Details

Roche PrevenTRON Study

Information

The Phase 3 PrevenTRON study will enroll 1,600 participants with biomarker evidence of amyloid but no cognitive or functional impairment. Participants will be selected based on plasma p-tau217, and must have a level consistent with a high likelihood of amyloid plaque burden on PET imaging. Participants will be randomized to intravenous 3.6 mg/kg trontinemab or placebo. They will begin with monthly dosing for six months, then switch to less frequent maintenance dosing.

To learn more, individuals can complete the form at the link provided. A Clinical Trial Educator will follow up to share additional details and answer any questions.

Interested in Participating?

If you are interested in participating, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.